Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report

References

• Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–150. doi:10.1016/j.eururo.2014.10.017
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health. 2020;8(2):e180–e190. doi:10.1016/S2214-109X(19)30488-7
   PubMed Web of Science ®Google Scholar
• Burgers JK, Badalament RA, Drago JR. Penile cancer: clinical presentation, diagnosis, and staging. Urol Clin North Am. 1992;19(2):247–256. doi:10.1016/S0094-0143(21)00387-6
   PubMed Web of Science ®Google Scholar
• Gu W, Zhang P, Zhang G, et al. Importance of HPV in Chinese penile cancer: a contemporary multicenter study. Front Oncol. 2020;10:1521. doi:10.3389/fonc.2020.01521
   PubMed Web of Science ®Google Scholar
• Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009;55(5):1075–1088. doi:10.1016/j.eururo.2009.02.021
   PubMed Web of Science ®Google Scholar
• Gakis G, Witjes JA, Compérat E, et al. EAU guidelines on primary urethral carcinoma. Eur Urol. 2013;64(5):823–830. doi:10.1016/j.eururo.2013.03.044
   PubMed Web of Science ®Google Scholar
• Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009;55(3):546–551. doi:10.1016/j.eururo.2008.07.014
   PubMed Web of Science ®Google Scholar
• Mistretta FA, Palumbo C, Knipper S, et al. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World J Urol. 2020;38(3):725–732. doi:10.1007/s00345-019-02869-6
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083. doi:10.1038/s41598-020-58674-4
   PubMed Web of Science ®Google Scholar
• Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH, Horenblas S, Jordanova ES. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J Urol. 2017;197(3 Pt 1):690–697. doi:10.1016/j.juro.2016.09.088
   PubMed Web of Science ®Google Scholar
• Chu C, Yao K, Lu J, et al. Immunophenotypes based on the tumor immune microenvironment allow for unsupervised penile cancer patient stratification. Cancers. 2020;12(7):1796.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Joshi SS, Handorf E, Strauss D, et al. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA Oncol. 2018;4(5):643–649. doi:10.1001/jamaoncol.2017.5608
   PubMed Web of Science ®Google Scholar
• Resch I, Abufaraj M, Hübner NA, Shariat SF. An update on systemic therapy for penile cancer. Curr Opin Urol. 2020;30(2):229–233. doi:10.1097/MOU.0000000000000733
   PubMed Web of Science ®Google Scholar
• Robinson R, Marconi L, MacPepple E, et al. Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy in node-positive penile cancer: a systematic review by the European association of urology penile cancer guidelines panel. Eur Urol. 2018;74(1):76–83. doi:10.1016/j.eururo.2018.04.003
   PubMed Web of Science ®Google Scholar
• Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006;93(2):133–138. doi:10.1002/jso.20414
   PubMed Web of Science ®Google Scholar
• Rodney S, Muneer A. HPV and penile cancer: perspectives on the future management of HPV-positive disease. Oncology. 2016;30(3):250–252.
   PubMed Web of Science ®Google Scholar
• Li ZS, Deng CZ, Yao K, et al. Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. J Cancer Res Clin Oncol. 2017;143(2):329–335. doi:10.1007/s00432-016-2292-3
   PubMed Web of Science ®Google Scholar
• Sirithanaphol W, Sookprasert A, Rompsaithong U, Kiatsopit P, Wirasorn K, Chindaprasirt J. Prognostic factors for penile cancer and survival in response to multimodality therapy. Res Rep Urol. 2020;12:29–34.
   PubMed Web of Science ®Google Scholar
• Dorff TB, Ballas LK, Schuckman AK. Current management strategy for penile cancer and future directions. Curr Oncol Rep. 2017;19(8):54. doi:10.1007/s11912-017-0615-4
   PubMed Web of Science ®Google Scholar
• Xu J, Li G, Zhu SM, et al. Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. BMC Cancer. 2019;19(1):625. doi:10.1186/s12885-019-5847-2
   PubMedGoogle Scholar
• Necchi A, Lo Vullo S, Nicolai N, et al. Prognostic factors of adjuvant taxane, cisplatin, and 5-fluorouracil chemotherapy for patients with penile squamous cell carcinoma after regional lymphadenectomy. Clin Genitourin Cancer. 2016;14(6):518–523. doi:10.1016/j.clgc.2016.03.005
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–3857.
   PubMed Web of Science ®Google Scholar
• Chahoud J, Skelton WP, Spiess PE, et al. Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab. Front Oncol. 2020;10:615298. doi:10.3389/fonc.2020.615298
   PubMed Web of Science ®Google Scholar
• Hui G, Ghafouri SN, Shen J, Liu S, Drakaki A. Treating penile cancer in the immunotherapy and targeted therapy era. Case Rep Oncol Med. 2019;2019:8349793. doi:10.1155/2019/8349793
   PubMed Web of Science ®Google Scholar
• Su X, Zhang J, Fu C, Xiao M, Wang C. Recurrent metastatic penile cancer patient with positive PD-L1 expression obtained significant benefit from immunotherapy: a case report and literature review. Onco Targets Ther. 2020;13:3319–3324. doi:10.2147/OTT.S231258
   PubMed Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–641. doi:10.1200/JCO.2017.75.3384
   PubMed Web of Science ®Google Scholar
• Stoehr R, Wendler O, Giedl J, et al. No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis. Pathobiology. 2019;86(2–3):145–151. doi:10.1159/000495251
   PubMed Web of Science ®Google Scholar
• Jiang H, Zheng Y, Qian J, et al. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer. 2020;20(1):760. doi:10.1186/s12885-020-07251-z
   PubMed Web of Science ®Google Scholar